India Pharma Outlook Team | Friday, 11 September 2026
MSD has inaugurated a technology center in Hyderabad’s HITEC City, expanding its role in the company’s global technology network.
The facility brings together capabilities spanning digital technology, data, analytics, artificial intelligence, engineering, and enterprise solutions.
The center was inaugurated by Telangana IT and Industries Minister D. Sridhar Babu.
The minister positioned the investment within the state’s effort to move its life sciences ecosystem beyond manufacturing into advanced research, innovation and global technology capabilities. He said Telangana was moving “from manufacturing scale to the next generation of discovery, innovation.”
MSD, the global biopharmaceutical company also known as Merck & Co. (Rahway, New Jersey), has opened a new technology centre in Hyderabad to support its Human Health business and wider global technology network. It is designed to enable Hyderabad-based teams to contribute to enterprise technology solutions and collaborate with MSD teams across global markets.
The Hyderabad center reflects a broader shift in how multinational pharma companies are structuring global capability operations. The new facility will support MSD’s global Human Health business through enterprise technology solutions and digital capabilities.
For MSD, the Hyderabad facility adds to its technology network. Its teams will work on enterprise solutions supporting the company’s global Human Health operations, giving the center a role that extends beyond local business requirements.
MSD’s digital leadership has also highlighted Hyderabad’s technology ecosystem and talent pool as factors supporting the company’s decision to establish the center in the city. Abhishek Narayan Singh, senior vice-president, digital human health, MSD, said Hyderabad’s technology ecosystem, digital expertise and talent pool made it an ideal location for the company.
Also Read: How Can India Pharma Bridge the Gap Between Innovation and Access
Several factors are strengthening Hyderabad’s position in the global pharma technology landscape:
These developments are strengthening Telangana’s technology, innovation and R&D ecosystem. The state’s Next-Gen Life Sciences Policy 2026–30 aims to bring discovery, manufacturing, clinical research and technology under a single ecosystem.
Telangana is positioning these investments as part of a broader effort to integrate manufacturing, research, clinical development and technology within one life sciences ecosystem. The state has more than 2,000 life sciences companies, while the government expects Telangana to soon reach 100 global capability centers, building on more than 75 established in the state last year.
These GCCs are expected to create four lakh direct and indirect high-value opportunities. The state is also developing a 2,100-acre life sciences zone, including a 100-acre advanced biologics hub, as part of Bharat Future City.
MSD’s new Technology Centre therefore adds another layer to Hyderabad’s pharma identity. The city is increasingly building its position across manufacturing, research, technology and global healthcare businesses.
